Management of Mixed Connective Tissue Disease with Joint Hypermobility

Immediate Diagnostic Priorities

The American College of Rheumatology recommends that all MCTD patients require baseline HRCT and pulmonary function tests at diagnosis, regardless of symptoms, as ILD occurs in 40-80% of MCTD patients and can progress asymptomatically to irreversible fibrosis 3, 4
Mortality reaches 20.8% in patients with severe pulmonary fibrosis versus 3.3% with normal HRCT, highlighting the importance of early diagnosis and treatment 3, 4
Risk factors for ILD progression include esophageal dysmotility, Raynaud phenomenon, anti-Ro-52 antibodies, rheumatoid factor, and high anti-RNP titers, which should be considered when assessing patient risk 3, 4

The American College of Rheumatology recommends mycophenolate as the preferred first-line agent for MCTD across all organ manifestations, particularly when ILD is present or suspected, due to its efficacy in preventing disease progression 1, 2
Azathioprine serves as an alternative first-line option if mycophenolate is contraindicated, providing an alternative treatment option for patients who cannot tolerate mycophenolate 1, 2

Implement joint stabilization exercises rather than stretching, as hypermobile joints require strengthening of periarticular muscles to prevent further injury and improve joint stability 6
Use compression garments for joint support, particularly if POTS is present, to help manage symptoms and improve patient comfort 6

If systemic sclerosis phenotype: PFTs every 6 months and HRCT annually for first 3-4 years to monitor for ILD progression and adjust treatment as needed 3, 4, 2
If other MCTD phenotypes: Annual PFTs with HRCT only if abnormalities detected, allowing for targeted monitoring and treatment of patients with different disease phenotypes 3, 4, 2

For progressive ILD despite mycophenolate: Add rituximab, cyclophosphamide, or nintedanib to the treatment regimen to address ongoing disease activity and prevent further progression 1, 2
Combination immunosuppression is preferred over sequential monotherapy in progressive disease, as it allows for more effective management of complex disease manifestations 1

Do not wait for symptoms to initiate pulmonary screening, as ILD progresses silently and becomes irreversible, highlighting the importance of proactive monitoring and early intervention 3, 4, 1
Do not use glucocorticoid monotherapy long-term, as it increases mortality without addressing underlying pathophysiology, and instead use combination therapy to achieve better disease control 1
Do not dismiss GI symptoms as functional, as they may indicate esophageal dysmotility predicting ILD or represent MCAS/POTS overlap, requiring further evaluation and targeted treatment 3, 6